We sought to describe the characteristics of adult patients with bronchiectasis enrolled in the US Bronchiectasis Research Registry (BRR).
Bronchiectasis is a chronic lung disease characterized by dilatation of airways, with injury to the bronchial walls due to recurrent infection and inflammation. It is typically distinguished by whether or not the patient has underlying cystic fibrosis (CF). Adult non-CF bronchiectasis (NCFB) is heterogeneous and has numerous causes. [1] [2] [3] [4] [5] Idiopathic bronchiectasis and infection-related bronchiectasis represent the majority of adult cases of NCFB in most series. [4] [5] [6] [7] [8] The prevalence of NCFB appears to be increasing in the United States. Seitz et al 9 analyzed a 5% sample of Medicare Part B beneficiaries and reported that from 2000 to 2007, the prevalence increased 8.74% annually. In addition, the prevalence of NCFB increases substantially with aging. 10 Furthermore, NCFB imposes a significant financial burden on patients and the US health-care system, with annual costs approximating $630 million. 10 Despite the significant morbidity of NCFB and significant financial burden, there are limited data regarding the characteristics of patients with NCFB in the United States. To better define the characteristics of patients with NCFB and provide a resource for clinical trials and other research, the Bronchiectasis Research Registry (BRR) was established within the COPD Foundation in 2008. The registry includes 13 sites across the country where patients are enrolled through a centralized database. As such, the BRR is not a tool to generate population-based prevalence data. To our knowledge, this is the first report describing the US BRR cohort.
Methods
The BRR is a centralized database of patients with bronchiectasis identified at 13 clinical sites throughout the United States (e-Appendix 1). Adult patients with a physician-established diagnosis of bronchiectasis were eligible for inclusion. The institutional review board of each participating site approved the study, as did an administrative institutional review board for the data collecting center (DCC). After providing informed consent, medical records were queried by a study coordinator or principal investigator using standardized recording forms. For purposes of this report, NCFB is heretofore labeled as bronchiectasis. The exclusion of patients with primary CF was established based on clinical history, previous sweat chloride test results, genetic testing results, or a combination, at the time of enrollment. Exacerbations were recorded based on historical information. Data were entered through a centralized Internet-based entry system at the University of North Carolina. Study coordinators received training from the DCC. Quality control occurred in real time, as the data management system incorporated expected range checks. The BRR is sponsored by the COPD Foundation.
Spirometry
Spirometric results measured closest to the time of enrollment were abstracted from patient records. Spirometric results were considered normal when the FEV 1 /FVC was $ 0.70 and the FVC and FEV 1 were > 80% of predicted. Airflow obstruction was defined as FEV 1 /FVC < 0.70 and was defined as mild, moderate, severe, and very severe obstruction with a FEV 1 of $ 80% predicted, $ 50% and < 80%, $ 30% and < 50%, and < 30% of predicted, respectively. 11 Patients in whom the FEV 1 /FVC was > 0.70 and the FVC was < 80% were labeled as having restriction. A bronchodilator response was considered present when the FEV 1 or FVC improved $ 12% after bronchodilator use.
Chest Imaging
Chest CT scans were read by principal investigators or site radiologists.
Microbiological Evaluation
A maximum of three respiratory culture results for bacteria, fungi, and mycobacteria (total of a maximum of nine culture results) were abstracted between the 2 years prior to and 90 days after enrollment, which was defined as the baseline period. We recorded positive culture results during the baseline period, and we subsequently stratified these results based on patients' nontuberculous mycobacteria (NTM) status. For the purposes of this analysis, we defined patients with NTM as those with either a reported history of pulmonary NTM disease prior to enrollment or those with one or more NTM isolates in respiratory specimen cultures within the baseline period, or both.
Treatment
Treatment information was abstracted across several domains, including the use of antibiotics, corticosteroids, or bronchodilators; medication for acid suppression; mucus-active agents; and measures to enhance bronchial hygiene. Categories of antibiotic use included antibiotics for exacerbation only, any suppressive antibiotic, rotation of oral suppressive antibiotics, or inhaled suppressive antibiotics. Measures to improve bronchial hygiene were defined as any nonpharmacologic measure to improve bronchial hygiene.
Statistical Analysis
The analysis population consisted of patients enrolled in the BRR as of July 1, 2014 findings, microbiological culture results, and therapies administered were summarized for all participants, with subsequent stratification based on NTM status, as already described. c 2 tests for categorical data and t tests for continuous data were used to compare patients with NTM and those without NTM for the subset of variables for which clinically meaningful relationships were hypothesized. These comparisons were considered exploratory, and no adjustment for potential confounding variables or multiple comparisons were made.
Results

Demographic and Baseline Characteristics
A total of 1,941 patients were enrolled in the BRR as of July 1, 2014. One hundred fifteen patients were subsequently excluded from analysis due to withdrawal of consent (19 patients), diagnosis of NTM without bronchiectasis (11 patients), missing identification of sex (24 patients), or missing NTM status (61 patients). The evaluable 1,826 patients with bronchiectasis enrolled between 2008 and 2014 were then categorized based on NTM status. Baseline information at the time of enrollment is detailed in Table 1 . The study population was predominantly composed of women (79%) and non-Hispanic white patients (89%). The mean age was 64 AE 14 years, with a diagnosis of bronchiectasis in most patients (77%) occurring between the ages of 50 and 79 years. Forty-seven percent had commercial insurance coverage and 47% had Medicare or Medicaid. Sixty percent were never smokers and 68% had a prior history of pneumonia. Three percent had primary ciliary dyskinesia, 3% had pectus excavatum, and 1% had HIV infection.
As also shown in Table 1 , 63% (1,158 of 1,826) had coexistent NTM. Patients with NTM compared with patients without NTM were older, diagnosed with bronchiectasis at a later age, predominantly women, and had a lower BMI. Gastroesophageal reflux disease (GERD) was present more frequently in those with NTM, whereas asthma, primary ciliary dyskinesia, and immunodeficiency were more common in those without NTM.
Exacerbations were reported at baseline in 64% of patients within the preceding 2 years. Patients with NTM had fewer exacerbations (2.7 AE 2.3) during the prior 2 years than did those without NTM (3.4 AE 3.3; P < .01) ( Table 1) . Table 2 summarizes respiratory symptoms. The most common symptoms included cough (73%) that was productive (53%), dyspnea (64%), and fatigue (50%). Fatigue and hemoptysis were more common in those with NTM, whereas cough was more common in those without NTM. Sweat chloride testing and CF nasal potential difference measurements were performed in 12% and 1.9% of patients, respectively; the results were abnormal in 9% and 11%, respectively (data not shown).
Spirometry
Eighty-five percent of patients had spirometric results reported. No significant difference was observed between patients with NTM and patients without NTM (Table 3) . Twenty-six percent had normal spirometric results. Fifty-one percent of patients had obstruction. Three-quarters of patients with obstruction (76%) fell into the mild to moderate category. Twenty percent of patients had suggestive restrictive impairment. Only 5% of patients had a response to aerosol bronchodilators.
Chest CT
CT scans were available for analysis from 1,553 patients (85%). The right middle lobe (RML) (69%) was the most commonly involved lobe, whereas the upper division of the left upper lobe (LUL) (44%) was the least commonly involved. RML, lingular, right upper lobe (RUL), and LUL airway dilation was more common in those with NTM (Fig 1) . A single lobe was involved in only 11% of patients and occurred more commonly in those without NTM (Table 4) . Sixty percent of patients had tree-inbud infiltrates, with involvement of all lobes including a higher percentage of tree-in bud infiltrates in patients with NTM. Mucoid impaction within the RML, lingula, and RUL was more common in patients with NTM (data not shown). In general, patients with NTM were more likely to have dilated airways, thickened walls, or mucoid impaction within the upper lobes, lingula, and middle lobes.
Microbiological Evaluation
Of 1,826 evaluable patients, 1,645 (90%) had at least one type of culture performed during the baseline period. This included 1,314 patients (72%) with one or more acid-fast bacillus (AFB) cultures, 1,406 (77%) with one or more bacterial cultures, and 1,087 patients (60%) with one or more fungal cultures performed. For patients with AFB cultures, 484 (37%) isolated Mycobacterium avium complex, 130 (10%) isolated M. abscessus/chelonae, and 90 (8%) isolated other mycobacterial or Nocardia species (Table 5) . Of those with bacterial cultures, 470 (33%) isolated Pseudomonas species and 170 (12%) isolated Inhaled steroids were used almost three times more commonly than were oral steroids (39% vs 13%). Inhaled bronchodilators were used in 61% of patients. Inhaled vs oral steroids were used less commonly in those with NTM compared with those without NTM (35% vs 45%; P < .01, and 10% vs 19%; P < .01, Percentages and other descriptive statistics calculated after excluding participants with missing data from the column total. Less than 1% of participants had missing data for all items except the following: age at diagnosis (30%), race/ethnicity (6%), primary insurance (8%), chest wall deformity (5%), history of pneumonia (4%), otitis or rhinosinusitis (14%), respiratory distress at birth (17%), COPD (3%), asthma (2%), GERD (2%), rheumatologic disease (3%), chronic ulcerative colitis or Crohn's disease (2%), primary immunodeficiency (3%), primary ciliary dyskinesia (2%), and prior tuberculosis (2%).
b P values for categorical variables are from c 2 tests, and from t tests for continuous variables comparing patients with NTM vs patients without NTM. respectively), as was the use of inhaled bronchodilators (56% vs 70%; P < .01). Medication for acid suppression was used in slightly greater than one-third of patients (37%); 86% of such substances were proton pump inhibitors (data not shown). No difference in the use of medication for acid suppression was reported in those with and those without NTM. Mucus-active agents were used in 24% of patients and included hypertonic saline in 76% of those using mucus-active agents (data not shown). These agents were used slightly more commonly in those without NTM.
Nonpharmacologic measures to improve bronchial hygiene were used in 56% of patients, including 48% of patients (825 of 1,719) using a flutter or positive expiratory pressure (PEP) valve. The overall use of chest percussion/postural drainage and high-frequency chest oscillation was similar at 16% and 15%, respectively. Those with NTM were more likely to use bronchial hygiene, chest percussion, or a flutter or PEP valve compared with those without NTM (59% vs 50%; P < .01; 19% vs 12%; P < .01; or 52% vs 40%; P < .01, respectively).
Discussion
This first report from the BRR describes the largest US cohort of patients with bronchiectasis to date. The registry has prospectively enrolled > 1,900 patients with NFCB, 1,826 of whom were evaluable. Most are Figure 1 -All lobes were involved; the RML (69%) was involved most and the upper division of the LUL (44%) was involved least. Except for the lower lobes, the other lobes were involved to a greater extent in NTM than in subjects without NTM. LUL ¼left upper lobe; NTM ¼ nontuberculous mycobacteria; RLL ¼ right lower lobe; RML ¼ right middle lobe; RUL ¼ right upper lobe.
non-Hispanic white women and lifelong nonsmokers. In this cohort, a large proportion of the patients had a history of NTM disease or had NTM isolated at their baseline evaluation. Although we identified important differences in patients with and those without NTM, it should be recognized that this registry was developed as a bronchiectasis registry. As such, NTM lung-diseasespecific data domains appropriate for a specific NTM lung disease registry were not collected. Nonetheless, our findings are in agreement with published data reporting that most patients with idiopathic bronchiectasis are female nonsmokers. [4] [5] [6] [7] [8] In addition, we report that those with NTM and bronchiectasis are more likely to be women, are less likely to have Pseudomonas isolated in sputum, and are older at the time of diagnosis than those without NTM. Participant met the inclusion criteria for bronchiectasis, but site with dilated airways not identified.
In agreement with previous studies, we also describe a broad spectrum of comorbidities associated with bronchiectasis. [1] [2] [3] 7, 8 Patients with asthma, primary immunodeficiency, and primary ciliary dyskinesia were less likely to have NTM, whereas those with GERD were more likely to have NTM. Prior investigations have demonstrated coexistent NTM lung disease and GERD. 12, 13 In this study, more than one-half of the subjects had evidence of airflow obstruction. Interestingly, one-fifth of the patients also had suggestion of restriction on spirometry. Worse lung function in bronchiectasis is associated with more involvement of bronchiectasis on CT scans, the presence of Pseudomonas species, [14] [15] [16] [17] [18] and the presence of COPD. 19 Response to bronchodilator journal.publications.chestnet.org use was documented in 5% of subjects, which is lower than has been reported previously. 20 There appeared to be no difference in spirometric results between those with NTM and those without in this cohort of patients, a finding that has not been well described previously.
This cohort includes descriptive high-resolution CT imaging findings in those with and those without NTM. Both diseases involve multiple lobes, although NTMassociated bronchiectasis involves upper lobe and middle lobe distribution more than non-NTM bronchiectasis does, as has been noted by others. [21] [22] [23] [24] Treatments for bronchiectasis varied widely within both groups of patients. Antibiotic use was common and nearly evenly split between antibiotics used for acute exacerbations only and suppressive antibiotics. Antibiotics for acute exacerbations only were more commonly used for those without NTM, and suppressive antibiotics were used more frequently in those with NTM. Designation of antibiotics used for NTM vs bronchiectasis was not specified. A relatively small percentage of patients with bronchiectasis used aerosol antibiotics, likely reflecting the lack of positive clinical trials in this population and the period of enrollment. Moreover, current practice patterns in the participating centers reflect the lack of data to support rotating oral antibiotics, which is similar to recommendations in published guidelines. 25 Even though there is a paucity of data to support its use, bronchodilator use was noted in more than one-half of patients with bronchiectasis and was more commonly used in those without NTM. Given the central role of mucociliary clearance and bronchial hygiene in the management of bronchiectasis, it is surprising that slightly more than one-half of patients used some measure to improve bronchial hygiene; the majority used a flutter or PEP valve. Consistent use of bronchial hygiene is in alignment with published literature and was used more often by those with NTM than by those without NTM. Percentages and other descriptive statistics calculated after excluding participants with missing data from the column total. Less than 1% of participants had missing data for all items except the following: antibiotics for acute exacerbations only (3%), any suppressive antibiotic (3%), rotating oral suppressive antibiotics (3%), aerosol suppressive antibiotics (4%), inhaled steroid (2%), any oral steroid (2%), inhaled bronchodilator (2%), medication for gastric acid suppression (2%), mucolytic agent (2%), measure to improve bronchial hygiene (5%), chest percussion/postdrainage (6%), uses flutter or Acapella valve (6%), uses high frequency chest oscillation (6%). There are several limitations to our study. Because this study describes a cohort of patients enrolled from tertiary referral institutions with interest in NTM lung disease, the demographic information described is potentially biased, including overrepresentation of patients with NTM. Moreover, there was a predominance of geographic groupings of participating sites in the eastern United States. The presence or absence of coexistent illnesses was based on history. It is difficult to ascertain if GERD or coexistent obstructive lung disease, or both, was truly present in conjunction with bronchiectasis or had been ascribed based on compatible symptoms or spirometric findings, or both.
In conclusion, the BRR has enrolled 1,826 evaluable patients with bronchiectasis from 13 sites across the United States. Despite baseline characteristics of the study population sharing phenotypic similarities, this study notes significant differences in patient groups with and without the presence of NTM.
